drugset / Trial / NCT07595913
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Comparator | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | ZG006 | Unknown | — | Intravenous |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |